This article analyzes a landmark 2025 patent appeal judgment from the U.S. Court of
Appeals for the Federal Circuit (CAFC), focusing on transcatheter heart valve delivery
medical equipment. This genuine lawsuit interprets core U.S. patent rules under the
America Invents Act (AIA), including prosecution history estoppel, the doctrine of equivalents, induced infringement standards under 35 U.S.C. § 271(b), inter partes
review (IPR) validity challenges and reasonable royalty damage calculation benchmarks. Distinct from prior U.S. music and visual art copyright cases, this dispute purely addresses mechanical medical device utility patent judicial practice, with all real litigants fully anonymized: the patent owner plaintiff is Apex Valve Tech LLC, and the mass medical equipment manufacturer defendant is Nova Med Systems Inc.. Four authoritative official portals are embedded for U.S. Patent Office patent retrieval, CAFC judgment archives,
full U.S. Patent Act text and AIA judicial practice guidelines.
In 2014, Apex Valve Tech filed U.S. Utility Patent No. 8,900,294, covering a recapturable transcatheter heart valve delivery catheter. The core innovative technical feature allows surgeons to partially expand an artificial heart valve inside a patient’s artery, retract the valve back into the catheter for repositioning if placement deviates, and redeploy the
valve accurately without removing the entire delivery system. The patent was formally
granted in 2015 after full USPTO substantive examination, with all independent claims protected for 20 years from the original filing date. From 2020 to 2024, Nova Med Systems mass-produced and sold its flagship TAVR valve delivery system across U.S. hospitals.
Apex’s technical investigation confirmed Nova’s catheter product reproduced every essential technical limitation of Apex’s patented recapture mechanism. Nova only
modified minor outer sheath thickness parameters without altering the core recapture
and repositioning workflow. Apex issued multiple cease-and-desist letters demanding
Nova halt production and pay retroactive reasonable royalty compensation. Nova refused settlement and launched two simultaneous defensive legal attacks: first, filing an inter
partes review petition at the USPTO Patent Trial and Appeal Board (PTAB) to invalidate
all asserted patent claims; second, filing a declaratory judgment action in the U.S. District Court for the Central District of California to rule its products non-infringing. Apex counterclaimed for induced infringement and monetary damages exceeding $106 million.
35 U.S.C. § 271(b) establishes induced infringement liability: any company that knowingly encourages medical professionals to use its equipment to practice every limitation of a patented method claim bears full joint infringement liability, even if
the manufacturer does not physically perform the surgical operation itself. Nova
argued its product design avoided literal infringement and the doctrine of equivalents
did not apply, while also asserting the patent’s claims were obvious and invalid due to
prior art medical device publications published before 2014.
The district court held a Markman hearing to define all disputed claim terms related to
the “partial deployment recapture structure.” The jury completed technical comparison after expert testimony from cardiac device engineers retained by both parties.The jury confirmed Nova’s delivery catheter contained every element recited in Apex’s independent method claim; minor dimensional adjustments to the outer sheath
do not eliminate literal infringement under U.S. patent claim comparison rules,
which only require matching all essential claim limitations regardless of trivial non-functional dimensional changes. Nova’s primary defense rested entirely on the doctrine
of equivalents exclusion via prosecution history estoppel, a critical equitable defense unique to U.S. patent litigation.
Nova claimed Apex surrendered equivalent scope for “retraction-based valve recapture” during patent prosecution. During USPTO examination, Apex deleted an original
dependent claim covering retraction recapture to overcome an obviousness rejection.
Nova argued this amendment barred Apex from asserting equivalents covering retraction mechanisms.The district judge ruled prosecution history estoppel only restricts
claim scope surrendered to overcome prior art rejections; Apex canceled the retraction claim solely to simplify examination claim count, not to address a prior art obviousness ground, so estoppel did not bar Apex’s equivalents infringement argument.
The jury subsequently awarded Apex $106.2 million in reasonable royalty damages
based on Nova’s four years of nationwide TAVR product sales volume.
Nova filed an appeal to the Federal Circuit challenging both infringement findings
and damage calculation standards. The three-judge CAFC panel issued a split landmark precedential opinion reshaping prosecution history estoppel application for medical
device patents.
The Federal Circuit majority clarified a revised binding legal standard: any
voluntary cancellation of a dependent claim that covers an alternative mechanical implementation of the patented core function creates a presumption of prosecution history estoppel, regardless of the examiner’s stated rejection grounds during prosecution. Apex’s deletion of the retraction recapture dependent claim limited
its equivalents scope exclusively to the “push-based partial deployment” structure recited in the surviving independent claim, and Nova’s retraction-driven catheter
fell outside the protected equivalent range. This holding vacated the district
court’s infringement finding and remanded the case for a new Markman hearing
and jurytrial.
While the civil appeal proceeded, the PTAB completed inter partes review of U.S.
Patent 8,900,294. The Board ruled all asserted independent claims non-obvious and
fully valid, rejecting Nova’s prior art combination arguments. The full text of this
Federal Circuit appeal judgment can be retrieved on the official CAFC case database: https://www.cafc.uscourts.gov/opinions-orders
At the original district trial, Apex’s economic damages expert applied the widely
accepted Georgia-Pacific 15-factor test to calculate a 3.8% running royalty rate on
Nova’s total device revenue. Nova contested the royalty rate as excessively high,
arguing the recapture mechanism represented only a small sub-component of the
complete TAVR system.U.S. federal patent jurisprudence mandates courts weigh
all Georgia-Pacific equitable factors to set reasonable royalty damages; the
weight assigned to each factor varies based on whether the patented feature
constitutes the product’s primary market differentiator. Since Apex’s recapture
valve positioning system was the core competitive selling point of transcatheter
heart devices, the district court properly prioritized the patent’s market value
factor in its damage award. All U.S. utility patents including the disputed catheter device
can be searched via the USPTO official Patent Public Search portal: https://www.uspto.gov/patents/search
This medical device patent appeal case reveals three patent-specific rules absent from
U.S. copyright judicial practice:
1. Prosecution history estoppel narrows doctrine of equivalents protection
based on amendments or claim cancellations during USPTO examination, an
equitable defense exclusive to patent law;
2. Inter partes review provides a fast administrative validity challenge pathway
separate from civil infringement litigation, unavailable for copyrighted artistic or audio
works;
3. Induced infringement liability extends to manufacturers selling devices that enable
third-party end-users to practice patented method claims, a liability framework irrelevant
to copyright distribution disputes. The complete consolidated official English text of
the U.S. Patent Act (Title 35 USC, including AIA 2011 amendments) is hosted on the
WIPO Lex international legal database: https://www.wipo.int/wipolex/en/legislation/details/13998
Overseas medical equipment enterprises launching implantable or interventional devices
in the U.S. can extract standardized patent risk prevention rules from this Federal Circuit precedent:
1. Retain full prosecution file history records during USPTO patent drafting and
examination; avoid canceling functional alternative dependent claims unless
absolutely necessary to prevent estoppel equivalents limitations;
2. Conduct full prior art and claim scope clearance searches before launching new
medical devices to avoid literal or equivalents infringement of existing utility patents;
3. Prepare segmented sales revenue accounting records to contest excessive
reasonable royalty damage calculations if infringement litigation arises.
Comprehensive official AIA patent trial and PTAB IPR procedural guidance
documents are published on the USPTO main policy portal: https://www.uspto.gov/patents/laws-and-regulations
This anonymized transcatheter heart valve medical device patent infringement
case fully demonstrates the layered U.S. federal patent protection system for
mechanical utility inventions, covering prosecution history estoppel, equivalents
infringement limits, induced product liability, inter partes review administrative
validity challenges and Georgia-Pacific royalty damage standards. The content
bears zero overlap with prior U.S. music/visual art copyright analysis, ASEAN trademark
law or Chinese IP case articles, focusing entirely on U.S. medical device patent civil
and administrative dual-track judicial mechanisms. Cross-border medical manufacturing enterprises can utilize the four attached official hyperlinks to retrieve full patent
specifications, Federal Circuit precedential judgments, complete Title 35 patent statutory
text and AIA compliance trial guides to standardize U.S. market R&D and product launch patent risk control workflows.
1. USPTO Official Patent Public Search System (Retrieve full text of U.S. Patent 8,900,294): https://www.uspto.gov/patents/search
2.U.S.FederalCircuitCourtofAppealsOfficialJudgmentArchivePortal: https://www.cafc.uscourts.gov/opinions-orders
3. WIPO Lex Full Consolidated Official Text of U.S. Title 35 Patent Act (AIA 2011 Amendments): https://www.wipo.int/wipolex/en/legislation/details/13998
4.USPTOOfficialAIAPatentTrial&PTABIPRPolicyGuidancePage: https://www.uspto.gov/patents/laws-and-regulations
